| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
Chitotriose trihydrochloride targets oxidative stress pathways. It inhibits hydrogen peroxide-induced benzoate hydroxylation in the presence of Cu2+ with an IC50 of 80 μM. It has orally bioactive and antioxidant effects. It does not have a specific protein target but acts as a free radical scavenger.
|
|---|---|
| ln Vitro |
In vitro, Chitotriose trihydrochloride inhibits hydrogen peroxide-induced benzoate hydroxylation in the presence of Cu2+ with an IC50 of 80 μM. It exhibits antioxidant activity. It is a chitosan oligosaccharide with orally bioactive properties.
|
| ln Vivo |
In vivo, Chitotriose trihydrochloride has orally bioactive and antioxidant effects. Its antioxidant activity suggests potential for protecting against oxidative stress-related diseases. Animal studies are needed to confirm its in vivo efficacy and safety.
|
| Enzyme Assay |
Cell-free assays for Chitotriose trihydrochloride: antioxidant activity is measured using DPPH, ABTS, and FRAP radical scavenging assays. Inhibition of hydroxylation is assessed by incubating the compound with hydrogen peroxide, Cu2+, and benzoate, and measuring hydroxylated products by HPLC or fluorescence. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
Cellular assays for Chitotriose trihydrochloride: cells are cultured and treated with Chitotriose trihydrochloride at concentrations of 0.1-100 µM for 24-72 hours. ROS levels are measured using DCFH-DA. Cell viability is measured by MTT assay. Antioxidant enzyme activities (SOD, CAT, GPx) are measured in cell lysates.
|
| Animal Protocol |
In vivo animal studies for Chitotriose trihydrochloride: animal models of oxidative stress (e.g., chemically induced oxidative damage) would be used. Animals are administered Chitotriose trihydrochloride orally at doses of 10-50 mg/kg. Oxidative stress markers, antioxidant enzyme activities, and tissue histology are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Chitotriose trihydrochloride: as a water-soluble oligosaccharide (MW 610.86), it may have limited oral bioavailability. It is likely metabolized by intestinal enzymes and microbiota. Storage: powder at -20°C for up to 3 years. Appearance: white to almost white powder to crystal. Purity (HPLC): min. 93.0 area%.
|
| Toxicity/Toxicokinetics |
Toxicity of Chitotriose trihydrochloride: comprehensive toxicity data are limited. As a chitosan oligosaccharide, it is generally considered safe at moderate doses. It is for research use only and not approved for clinical use.
|
| References | |
| Additional Infomation |
Chitotriose trihydrochloride is a research compound with potential applications in antioxidant research. It is a chitosan oligosaccharide used as a reference standard for oligosaccharide analysis. Its mechanism involves free radical scavenging. No clinical trials or FDA approvals have been reported.
|
| Molecular Formula |
C18H38CL3N3O13
|
|---|---|
| Molecular Weight |
610.87
|
| Exact Mass |
609.147
|
| CAS # |
117436-78-9
|
| Related CAS # |
Chitotetraose tetrahydrochloride;117399-50-5;Chitopentaose pentahydrochloride;117467-64-8;Chitobiose dihydrochloride;115350-24-8;Chitohexaose hexahydrochloride;127171-88-4;Chitoheptaose heptahydrochloride;127171-89-5;Chitobiose;577-76-4
|
| PubChem CID |
70702331
|
| Appearance |
Typically exists as solid at room temperature
|
| Melting Point |
255 °C
|
| Hydrogen Bond Donor Count |
14
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
37
|
| Complexity |
652
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
Cl[H].Cl[H].Cl[H].O1C([H])(C([H])([H])O[H])[C@]([H])(C([H])([C@@]([H])([C@]1([H])O[C@]1([H])C([H])(C([H])([H])O[H])OC([H])([C@]([H])(C1([H])O[H])N([H])[H])O[H])N([H])[H])O[H])O[C@@]1([H])[C@]([H])(C([H])([C@@]([H])(C([H])(C([H])([H])O[H])O1)O[H])O[H])N([H])[H]
|
| InChi Key |
XTVOJWIUUCPOIF-VMCMTGCNSA-N
|
| InChi Code |
InChI=1S/C18H35N3O13.3ClH/c19-7-12(27)14(5(2-23)30-16(7)29)33-18-9(21)13(28)15(6(3-24)32-18)34-17-8(20)11(26)10(25)4(1-22)31-17;;;/h4-18,22-29H,1-3,19-21H2;3*1H/t4?,5?,6?,7-,8-,9-,10+,11?,12?,13?,14+,15+,16+,17-,18-;;;/m0.../s1
|
| Chemical Name |
(3S,5S,6S)-5-amino-6-[(3S,5S,6S)-5-amino-6-[(3S,5S,6R)-5-amino-4,6-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-2-(hydroxymethyl)oxane-3,4-diol;trihydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6370 mL | 8.1850 mL | 16.3701 mL | |
| 5 mM | 0.3274 mL | 1.6370 mL | 3.2740 mL | |
| 10 mM | 0.1637 mL | 0.8185 mL | 1.6370 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
